Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regenxbio

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

The U.S. Food and Drug Administration (FDA) on Monday extended its review timeline for REGENXBIO Inc.’s (NASDAQ:RGNX) Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Investors Business Daily

Goldman Sachs Expects Market Sentiment To Support Smaller Firms, Sees Upside of up to 165% for Two Biotech Stocks

Goldman Sachs Expects Market Sentiment To Support Smaller Firms, Sees Upside of up to 165% for Two Biotech Stocks

Goldman Sachs analysts believe small- and equal-weight benchmarks will keep outperforming unless Q2 reports of big tech companies lead analysts to bump their sales forecasts for the latter half of this year and 2025.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.

Investors Business Daily

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.

Investors Business Daily

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Expert Ratings for Regenxbio

Analysts have provided the following ratings for Regenxbio (NASDAQ:RGNX) within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Regenxbio's Return On Capital Employed Overview

Regenxbio's Return On Capital Employed Overview

Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million.

Expert Ratings for Regenxbio

Expert Ratings for Regenxbio

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

5 Value Stocks In The Healthcare Sector

5 Value Stocks In The Healthcare Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Expert Ratings for Regenxbio

Expert Ratings for Regenxbio

Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:

Regenxbio's Return On Capital Employed Overview

Regenxbio's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65 million in sales, a 1195.47% increase since Q3.

Expert Ratings For Regenxbio

Expert Ratings For Regenxbio

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Regenxbio: Q4 Earnings Insights

Regenxbio: Q4 Earnings Insights

Regenxbio (NASDAQ:RGNX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Regenxbio beat estimated earnings by 41.61%, reporting an EPS of $6.67 versus an estimate of $4.71.

Get all your
news in one place.

100’s of premium titles.
One news app.

Earnings Preview: Regenxbio

Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will report an earnings per share (EPS) of $4.71.

Expert Ratings For Regenxbio

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

People

Joseph Schwartz

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Walgreens Boots Alliance

European Medicines Agency

Sarepta Therapeutics

Viridian Therapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prostate Cancer

Ulcerative Colitis

Places

301,890 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play